Literature DB >> 3948301

The effect of disulfiram on cyclophosphamide-mediated myeloid toxicity.

R L Gamelli, W B Ershler, M P Hacker, R S Foster.   

Abstract

We have previously shown that disulfiram (DSF) blocks the urotoxicity of cyclophosphamide (CYT) in mice and increases the oncolytic effect of CYT in the L1210 murine leukemia. However, mice treated with CYT and DSF appeared to have longer-lasting neutropenia than animals treated with CYT alone. To determine whether DSF uroprotection of CYT-treated mice was associated with increased myeloid toxicity, we examined the effects of DSF plus CYT treatment on the bone marrow granulocyte/macrophage progenitor cell (GM-CFC). Marrow cellularity and GM-CFC numbers were analyzed at 1, 2 and 3 days after injection of CYT (62.5 or 125 mg/kg) or CYT plus DSF (200 mg/kg). CYT alone caused a decrease in total marrow cellularity varying from 20% to 50% of control. Animals given CYT plus DSF had a somewhat greater decrease in total marrow cellularity than those treated with CYT alone. However, in mice treated with CYT plus DSF, the GM-CFC were relatively well preserved and the recovery of the GM-CFC was not prolonged by DSF. It appears from these studies that the acute toxic effect of CYT on the granulocyte/macrophage progenitor cells is not enhanced by DSF.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3948301     DOI: 10.1007/bf00256166

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  12 in total

1.  The growth of mouse bone marrow cells in vitro.

Authors:  T R Bradley; D Metcalf
Journal:  Aust J Exp Biol Med Sci       Date:  1966-06

2.  Effect of disulfiram on cyclophosphamide toxicity: a clinical trial.

Authors:  W B Ershler; M P Hacker; R A Newman; J A Stewart; R L Gamelli; I H Krakoff
Journal:  Cancer Treat Rep       Date:  1983-12

3.  Phase I clinical study of acetylcysteine's preventing ifosfamide-induced hematuria.

Authors:  M Slavik; J H Saiers
Journal:  Semin Oncol       Date:  1983-03       Impact factor: 4.929

4.  Distribution of S35 disulfiram and metabolites in mice, and metabolism of S35 disulfiram in the dog.

Authors:  M D Faiman; D E Dodd; R E Hanzlik
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1978-09

5.  Effect of ureteral ligation and nephrectomy on granulocyte-macrophage progenitor cells and azathioprine toxicity.

Authors:  R L Gamelli; R S Foster
Journal:  Transplantation       Date:  1979-09       Impact factor: 4.939

6.  Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.

Authors:  N Brock; J Stekar; J Pohl; U Niemeyer; G Scheffler
Journal:  Arzneimittelforschung       Date:  1979

7.  Effect of disulfiram (tetraethylthiuram disulfide) amd diethyldithiocarbamate on the bladder toxicity and antitumor activity of cyclophosphamide in mice.

Authors:  M P Hacker; W B Ershler; R A Newman; R L Gamelli
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

8.  The prevention of cyclophosphamide-induced cystitis in mice by disulfiram.

Authors:  M P Hacker; R A Newman; W B Ershler
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1982-01

9.  Protective role of thiols in cyclophosphamide-induced urotoxicity and depression of hepatic drug metabolism.

Authors:  M J Berrigan; A J Marinello; Z Pavelic; C J Williams; R F Struck; H L Gurtoo
Journal:  Cancer Res       Date:  1982-09       Impact factor: 12.701

10.  Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.

Authors:  B M Bryant; M Jarman; H T Ford; I E Smith
Journal:  Lancet       Date:  1980-09-27       Impact factor: 79.321

View more
  1 in total

Review 1.  Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity.

Authors:  Maricela Viola-Rhenals; Kush R Patel; Laura Jaimes-Santamaria; Guojun Wu; Jinbao Liu; Q Ping Dou
Journal:  Curr Med Chem       Date:  2018-02-12       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.